GSK
GSK
910 hedge funds and large institutions have $13.3B invested in GSK in 2024 Q1 according to their latest regulatory filings, with 99 funds opening new positions, 326 increasing their positions, 300 reducing their positions, and 77 closing their positions.
79% more call options, than puts
Call options by funds: $195M | Put options by funds: $109M
29% more first-time investments, than exits
New positions opened: 99 | Existing positions closed: 77
20% more capital invested
Capital invested by funds: $11.1B → $13.3B (+$2.2B)
8% more funds holding in top 10
Funds holding in top 10: 13 → 14 (+1)
2% more funds holding
Funds holding: 895 → 910 (+15)
9% more repeat investments, than reductions
Existing positions increased: 326 | Existing positions reduced: 300
0.23% more ownership
Funds ownership: 7.28% → 7.51% (+0.23%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JEST
JTC Employer Solutions Trustee
St Helier,
Jersey
|
+$363M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$215M |
| 3 |
Citigroup
New York
|
+$81M |
| 4 |
MIP
Mondrian Investment Partners
London,
United Kingdom
|
+$62.4M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$58.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$191M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$112M |
| 3 |
Millennium Management
New York
|
-$59.2M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$55.8M |
| 5 |
MIS
Morningstar Investment Services
Chicago,
Illinois
|
-$52.6M |
GSK Hedge Fund Activity: Q1 2024 in Review
910 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q1 2024, worth a combined $13.3B — up 20% from $11.1B a quarter earlier.
Buyers outnumbered sellers: 99 funds opened new GSK positions and 77 closed out — a net gain of 22 holders — while 326 added to existing stakes and 300 trimmed.
The largest buyer was JTC Employer Solutions Trustee, adding an estimated $363M. The largest seller was Morgan Stanley, cutting an estimated $191M.
- 910 institutional investors held GSK (GSK) as of Q1 2024, up from 895 in Q4 2023.
- Funds reported $13.3B of GSK stock for Q1 2024, up 20% quarter-over-quarter.
- 99 funds opened new GSK positions in Q1 2024 and 77 closed out, a net change of +22 holders.
- The largest GSK buyer in Q1 2024 was JTC Employer Solutions Trustee, an estimated $363M added.
- The largest GSK seller in Q1 2024 was Morgan Stanley, an estimated $191M sold.
Based on aggregated 13F filings for Q1 2024.